Clinical Trials Browser

Phase 2 × Withdrawn × binimetinib × Clear all

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase 2 Withdrawn

Melanoma